Skip to Content
Merck

Skip To

KMP4G05TH1

Millipore

Milligard® PES 1.2/0.45 µm, Opticap® XL Capsule

Opticap® XL 5

Sign Into View Organizational & Contract Pricing

Select a Size

5 ML
CA$213.00
25 ML
CA$893.00

CA$213.00


Please contact Customer Service for Availability

Select a Size

Change View
5 ML
CA$213.00
25 ML
CA$893.00

About This Item

UNSPSC Code:
41116105

CA$213.00


Please contact Customer Service for Availability

Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

material

polyester support
polyethersulfone membrane (PES)
polypropylene housing
silicone O-ring

Quality Level

sterility

non-sterile

Sterilization Compatibility

gamma compatible

product line

Opticap® XL 5

feature

hydrophilic

technique(s)

bioburden reduction: suitable

L

8.5 in.

W

4.2 in.

core size

, polypropylene

Looking for similar products? Visit Product Comparison Guide

Compare Similar Items

View Full Comparison

Show Differences

1 of 4

This Item
CAD6170CAD6183CAD6171
manufacturer/tradename

Cadence Science 6163

manufacturer/tradename

Cadence Science 6170

manufacturer/tradename

Cadence Science 6183

manufacturer/tradename

Cadence Science 6171

packaging

pack of 10 ea

packaging

pack of 10 ea

packaging

pack of 10 ea

packaging

pack of 10 ea

General description

Milligard® PES 1.2/0.45 µm filters are designed for effective bioburden control and reliable particulate removal from a broad range of fluid streams. When used standalone for non critical applications, these membrane-based filters typically remove ≥ 6 log Serratia marcescens. When used upstream of sterilizing-grade filters or other unit operations, they improve processing efficiency.Milligard® PES filters are supported by the Emprove® Program which consolidates product specific testing, quality and regulatory information to simplify compliance needs.

Application

Prefiltration and bioburden control

Features and Benefits

  • Fast flow and high throughput
  • Validated bioburden reduction
  • Predictable scalability from small-scale to production-size devices
  • High thermal stability: compatible with steam-in-place and autoclave sterilization methods
  • Single-use, gamma-ready formats
  • Caustic stable

Packaging

PE Bag

Other Notes

Directions for Use

Organism Retention: Microorganism

Mode of Action: Filtration (size exclusion)

Application: BioProcessing

Intended Use: Reduction or removal of microorganism/bioburden

Instructions for Use: Please refer to Opticap® Small Scale 300 Capsule, XL, XLT and T-line Capsules User Guide

Storage Statement: Store in dry location

Disposal Statement: Dispose of in accordance with applicable federal, state and local regulations.

Legal Information

Emprove is a registered trademark of Merck KGaA, Darmstadt, Germany
MILLIGARD is a registered trademark of Merck KGaA, Darmstadt, Germany
OPTICAP is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

Filters are designed, developed and manufactured in accordance with a Quality Management System approved by an accredited registering body to the ISO 9001 Quality Systems Standard. Certificate of Quality is available online for all filters.

  • Certificates of Analysis (COA)

    Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

    Already Own This Product?

    Find documentation for the products that you have recently purchased in the Document Library.

    Visit the Document Library

    Recommendations for the management of Acanthamoeba keratitis.
    Abdul Mannan Baig et al.
    Journal of medical microbiology, 63(Pt 5), 770-771 (2014-02-11)
    Brian L Le et al.
    Research square (2021-04-07)
    The novel SARS-CoV-2 virus emerged in December 2019 and has few effective treatments. We applied a computational drug repositioning pipeline to SARS-CoV-2 differential gene expression signatures derived from publicly available data. We utilized three independent published studies to acquire or
    Gideon Koren
    American journal of obstetrics and gynecology, 211(6), 602-606 (2014-08-26)
    Presently, 97.7% of prescriptions for the treatment of nausea and vomiting in pregnancy in the United States are with medications not labeled for use in pregnancy, not indicated for nausea and vomiting in pregnancy, and not classified as safe in

    Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

    Contact Technical Service